A comparison between patients who suffer from major depression and are treated with Esketamine – one group participates in group therapy and the other one does not
Introduction Major depressive disorder is present in approximately 7% of the general population. There are some patients that remain treatment-resistant - patients who were treated with two or more different medications and did not demonstrate any improvement in their mental state. These patients c...
Main Authors: | H. Yaniv, V. Savlev |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-06-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822014365/type/journal_article |
Similar Items
-
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial
by: Haiyan Liu, et al.
Published: (2022-11-01) -
Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder
by: A. Safai Pour, et al.
Published: (2022-12-01) -
Esketamine, a new treatment for resistant depression: a systematic review of the literature
by: Mercedes Valtueña García, et al.
Published: (2021-07-01) -
The effects of esketamine and treatment expectation in acute major depressive disorder (Expect): study protocol for a pharmacological fMRI study using a balanced placebo design
by: Irina Falkenberg, et al.
Published: (2023-08-01) -
The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
by: Ludivine Boudieu, et al.
Published: (2023-12-01)